health NHS Greenlights Revolutionary Ovarian Cancer Drug After Two-Decade Hiatus
NHS approves AbbVie's targeted therapy mirvetuximab soravtansine for platinum resistant ovarian cancer, extending survival and marking the first new treatment in 20 years.
